Clinical Trial Update: A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients [Phase 3]

View source ↗

Summary

A completed Phase 3 trial compares several COPD therapies, including Symbicort pMDI with different budesonide/formoterol doses, Formoterol Turbuhaler, Budesonid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide pMDI (budesonide)
• Formoterol Turbuhaler (formoterol)
• Symbicort pMDI (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED